EUVIMEDEUVIMED entdecken
Leserbrief

Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System

Magdi Elsallab iD, Moataz Ellithi iD, Matthew A Lunning iD, Christopher D'Angelo iD, Jihyun Ma, Miguel-Angel Perales iD, Matthew Frigault, Marcela V Maus iD

Blood · 16.05.2024 · 143 (20) · 2099-2105

DOI: 10.1182/blood.2024024166 ↗

Kurz gefasst

Leserbrief in der Zeitschrift Blood, erschienen am 16.05.2024. Verfasst von Magdi Elsallab und 7 weiteren Autor:innen. Beteiligte Einrichtung: Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Neoplasms, Second Primary, United States Food and Drug Administration, Immunotherapy, Adoptive, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 165-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Second primary malignancies were reported in 536 of 12 394 (4.3%) adverse event reports following chimeric antigen receptor T-cell therapies in the Food and Drug Administration Adverse Event Reporting System. Myeloid and T-cell neoplasms were disproportionately more frequently reported, warranting further follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Neoplasms, Second PrimaryUnited States Food and Drug AdministrationImmunotherapy, AdoptiveAdverse Drug Reaction Reporting SystemsHumansUnited StatesMaleReceptors, Chimeric AntigenFemaleMiddle AgedAdultAged

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • Harvard-MIT Center for Regulatory Science, Harvard Medical School, Boston, MA.
  • Cellular Immunotherapy Program, Mass General Cancer Center, and Department of Medicine, Harvard Medical School, Boston, MA.
  • Fred & Pamela Buffett Cancer Center, Division of Hematology-Oncology, University of Nebraska Medical Center, Omaha, NE.
  • Department of Biostatistics, University of Nebraska Medical Center, Omaha, NE.
  • Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.
  • Department of Medicine, Weill Cornell Medical College, New York, NY.

ORCID-Profile: Magdi Elsallab, Moataz Ellithi, Matthew A Lunning, Christopher D'Angelo, Miguel-Angel Perales, Marcela V Maus

Zitieren

APA

Elsallab, M., Ellithi, M., Lunning, M. A., D'Angelo, C., Ma, J., Perales, M. A., Frigault, M., & Maus, M. V. (2024). Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood, 143(20), 2099-2105. https://doi.org/10.1182/blood.2024024166

Vancouver

Elsallab M, Ellithi M, Lunning MA, D'Angelo C, Ma J, Perales MA, et al. Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System. Blood. 2024;143(20):2099-2105. doi:10.1182/blood.2024024166

BibTeX
@article{Elsallab2024,
  author = {Elsallab, Magdi and Ellithi, Moataz and Lunning, Matthew A and D'Angelo, Christopher and Ma, Jihyun and Perales, Miguel-Angel and Frigault, Matthew and Maus, Marcela V},
  title = {Second primary malignancies after commercial CAR T-cell therapy: analysis of the FDA Adverse Events Reporting System},
  journal = {Blood},
  year = {2024},
  volume = {143},
  number = {20},
  pages = {2099--2105},
  doi = {10.1182/blood.2024024166}
}
Kostenlos starten →